Gracell Biotechnologies (GRCL)
NASDAQ:GRCL
US Market

Gracell Biotechnologies (GRCL) Stock Price & Analysis

90 Followers

GRCL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.40 - $5.69
Previous Close$3.06
Volume86.25K
Average Volume (3M)111.14K
Market Cap
$207.16M
Enterprise Value$22.27M
Total Cash (Recent Filing)¥211.42M
Total Debt (Recent Filing)¥26.53M
Price to Earnings (P/E)-2.4
Beta-0.38
Aug 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding67,720,000
10 Day Avg. Volume145,687
30 Day Avg. Volume111,135
Standard Deviation0.28
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.13
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside300.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4


Financials

Annual

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

GRCL FAQ

What was Gracell Biotechnologies’s price range in the past 12 months?
Gracell Biotechnologies lowest stock price was $1.40 and its highest was $5.69 in the past 12 months.
    What is Gracell Biotechnologies’s market cap?
    Currently, no data Available
    When is Gracell Biotechnologies’s upcoming earnings report date?
    Gracell Biotechnologies’s upcoming earnings report date is Aug 15, 2023 which is in 71 days.
      How were Gracell Biotechnologies’s earnings last quarter?
      Gracell Biotechnologies released its earnings results on May 15, 2023. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.069 by -$0.001.
        Is Gracell Biotechnologies overvalued?
        According to Wall Street analysts Gracell Biotechnologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Gracell Biotechnologies pay dividends?
          Gracell Biotechnologies does not currently pay dividends.
          What is Gracell Biotechnologies’s EPS estimate?
          Gracell Biotechnologies’s EPS estimate is -$0.07.
            How many shares outstanding does Gracell Biotechnologies have?
            Gracell Biotechnologies has 67,715,240 shares outstanding.
              What happened to Gracell Biotechnologies’s price movement after its last earnings report?
              Gracell Biotechnologies reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.069. Following the earnings report the stock price went up 9.314%.
                Which hedge fund is a major shareholder of Gracell Biotechnologies?
                Among the largest hedge funds holding Gracell Biotechnologies’s share is Viking Global Investors LP. It holds Gracell Biotechnologies’s shares valued at N/A.

                  ---

                  Gracell Biotechnologies Stock Smart Score

                  The Gracell Biotechnologies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Gracell Biotechnologies

                  Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfil unmet medical needs in the treatment of cancer.

                  ---

                  Top 5 ETFs holding GRCL

                  Name
                  Market Value
                  Smart Score
                  iShares Biotechnology ETF
                  $897.30K
                  8
                  Invesco Golden Dragon China ETF
                  $195.56K
                  8
                  iShares NASDAQ US Biotechnology UCITS ETF
                  $92.96K
                  8
                  Invesco Nasdaq Biotechnology ETF
                  $3.55K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold GRCL. The ETFs are listed according to market value of GRCL within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Oncternal Therapeutics
                  Moderna
                  Crispr Therapeutics AG
                  Editas Medicine

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis